Interventional Glaucoma

The Reichert 7, a seventh-generation non-contact tonometer (NCT) with integrated one-touch measurement system, has been launched by Reichert Inc.

Azarga (brinzolamide 1%/timolol 0.5% ophthalmic suspension; Alcon Laboratories) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which recommends Azarga be granted marketing authorization from the European Medicines Agency (EMEA).

There are several factors that might increase the risk of uncontrolled intraocular pressure (IOP) after phacoviscocanalostomy combination surgery, according to study results published in the September 2008 issue of Journal of Glaucoma.

Perioperative use of mitomycin-C (MMC) improves the long-term outcomes of trabeculectomy as a treatment for primary open-angle glaucoma (POAG), according to a study published online ahead of print by the British Journal of Ophthalmology.

Optical is just as good as digital pachymetry say Mohammed Hassan & Ali Yagan

Eighteen-month results confirm safety & efficacy says Dr Norbert Koerber.

Dr James Tsai outlines key points to ensure a good outcome.

Survey reveals ophthalmologists' concerns relating to BAK-containing eye drops and the incidence of dry eye

US documentary film director Joseph Lovett discusses his latest film project, which he hopes will change public and ophthalmologists' perception of blindness.

The body mass index (BMI) of a patient may affect the results of a water-drinking test (WDT), according to study results published in October issue of the Journal of Ocular Pharmacology and Therapeutics.

Goldmann applanation tonometry (GAT) and dynamic contour tonometry (DCT) do not produce identical results when measuring intraocular pressure (IOP), according to study results published in the September 2008 issue of the Journal of Glaucoma.

Othera Pharmaceuticals' topical beta blocker, OT-730, indicated for the reduction of intraocular pressure (IOP) in subjects with ocular hypertension and open-angle glaucoma, has begun a Phase I/II clinical trial for safety and efficacy.

SOLX 790, a glaucoma laser, has received 510(k) clearance from the FDA and can now be used for Titanium:Sapphire laser trabeculoplasty (TLT) in the United States, the laser's manufacturer, SOLX, has announced.

iScience Interventional has been granted 510k clearance from the FDA for its canaloplasty microcatheter for the catheterization and viscodilation of the Schlemm's canal in adult patients with primary open-angle glaucoma (POAG).

A study published in the September issue of the British Journal of Ophthalmology, has discovered that wearing swimming goggles may elevate intraocular pressure (IOP).

There is a large variation in the blood flow to the macula across a 24-hour period in old, but not young, eyes, according to results published in the August issue of the Journal of Glaucoma.

Ophthalmologists today are more likely to begin treatment to reduce intraocular pressure (IOP) at lower levels than twenty years ago, according to a study published in the Journal of Glaucoma, August 2008.

Understanding the glaucoma continuum enables earlier detection and better monitoring of the disease, according to Dr Theodore Krupin.

Pfizer has announced that it does not plan to begin a Phase III trial of its experimental compound PF-03187207 for glaucoma and ocular hypertension in Asia.

Augmenting combined phacoemulsification and deep sclerectomy (PDS) with intraoperative mitomycin C (MMC) is safe and likely to produce lower intraocular pressure (IOP) values than conducting PDS without MMC, according to the results of a study published in the August 2008 issue of Eye.

Many UK institutions are not compliant with current international guidelines on tonometer disinfection, according to a study published in the August 2008 issue of Eye.

Glaucoma patients are at an increased risk of developing ocular surface disease (OSD) in at least one eye, according to a study published in the August 2008 issue of the Journal of Glaucoma.

The protein/peptide patterns in the aqueous humour of primary open-angle glaucoma (POAG) subjects differs significantly from that of control subjects, according to a study published in the August 2008 issue of Molecular Vision.

Patients with glaucoma are not at an increased risk of developing systemic vascular disease, according to a study published in the August 2008 issue of the Acta Ophthalmologica.

Glaucoma treatment can, in certain metrics, improve quality of vision, according to a study published in the August 2008 issue of Eye.